Abstract
significantly attenuated (P<0.05 and <0.001) by bosentan (50 and 100mg/kg perorally) treatment. An upregulation in the mRNA expression of endothelin-1 was significantly (P<0.05 and <0.001) attenuated by bosentan (50 and 100mg/kg perorally) treatment. Histological aberration induced after pressure overload was restored by bosentan treatment. Conclusion Bosentan attenuates the development of cardiac hypertrophy by blocking the endothelin-1 receptor and improving left ventricular function; it also ameliorates endogenous biomarkers in pressure overload-induced cardiac hypertrophy in rats. Cardiovasc Endocrinol 2:85–97 � c 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
